Premium
Premature luteinization defined as progesterone estradiol ratio >1 on hCG administration day seems to adversely affect clinical outcome in long gonadotropin‐releasing hormone agonist cycles
Author(s) -
Özçakir Hasan Tayfun,
Levi Rafael,
Tavmergen Erol,
Göker Ege Nazan Tavmergen
Publication year - 2004
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2003.00166.x
Subject(s) - human chorionic gonadotropin , medicine , gonadotropin , gonadotropin releasing hormone agonist , agonist , hormone , endocrinology , infertility , pregnancy , gonadotropin releasing hormone , receptor , luteinizing hormone , biology , genetics
Aim: To examine the effect of premature luteinization on the outcomes in long gonadotropin‐releasing hormone agonist cycles. Methods: Two‐hundred and forty‐eight patients who had undergone assisted reproductive technology for infertility treatment between 2001 and 2002 were enrolled into the study. The patients were separated into two groups according to P/E2 ratios on human chorionic gonadotropin administration day. Group A consisted of the patients whose P/E2 ratio was 1 ( n = 116) and Group B consisted of the patients with premature luteinization of which P/E2 ratio was > 1 ( n = 132). The P/E2 ratio calculation was performed as follows: P (in ng/mL) × † 1,000/E2 (in pg/mL). The primary outcome measures included oocyte quality, fertilization rates and clinical pregnancy rates. Results: The mean number of mature oocytes retrieved in the groups were 9.5 ± 4.8 and 6.4 ± 3.6, respectively, and the difference was statistically significant ( P < 0.05). Although the difference between the fertilization rates in Group A and Group B was not statistically significant ( P > 0.05), the clinical pregnancy rates seemed to be affected adversely in the Group B patients with premature luteinization (41.4% versus 28%, respectively; P < 0.05). Conclusion: Premature luteinization, defined as P/E2 > 1 on human chorionic gonadotropin administration day, in long gonadotropin‐releasing hormone agonist cycles seems to adversely affect clinical outcome.